These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26091546)

  • 21. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medications for Obesity: A Review.
    Gudzune KA; Kushner RF
    JAMA; 2024 Aug; 332(7):571-584. PubMed ID: 39037780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.
    Lee K; Abraham S; Cleaver R
    Gen Hosp Psychiatry; 2022; 78():58-67. PubMed ID: 35863294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mysimba, an American appetite suppressant and the logic of the single European market].
    Nau JY
    Rev Med Suisse; 2015 Apr; 11(470):890-1. PubMed ID: 26050313
    [No Abstract]   [Full Text] [Related]  

  • 28. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
    Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Brown SA; Izzy M; Watt KD
    Hepatology; 2021 May; 73(5):2051-2062. PubMed ID: 33047343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Caixàs A; Albert L; Capel I; Rigla M
    Drug Des Devel Ther; 2014; 8():1419-27. PubMed ID: 25258511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 34. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacotherapy for obesity].
    van Rossum EFC; Welling MS; van der Voorn B; van der Valk ES; Abawi O; van den Akker ELT
    Ned Tijdschr Geneeskd; 2021 Jan; 165():. PubMed ID: 33560612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Smith SR; Fujioka K; Gupta AK; Billes SK; Burns C; Kim D; Dunayevich E; Greenway FL
    Diabetes Obes Metab; 2013 Sep; 15(9):863-6. PubMed ID: 23489381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
    Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
    Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is cardiometabolic risk improved by weight-loss drugs?
    Astrup A
    Lancet; 2010 Aug; 376(9741):567-8. PubMed ID: 20673996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.